Simplex Trading, LLC Clovis Oncology, Inc. Transaction History

Simplex Trading, LLC

$2.81 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$0.63 - $2.96 $31,806 - $149,438	-50,486 Reduced 33.69%	99,358 $178,000
Q1 2022 May 02, 2022	BUY	$1.43 - $3.14 $164,883 - $362,051	115,303 Added 333.81%	149,844 $302,000
Q4 2021 Feb 23, 2022	BUY	$2.7 - $4.76 $86,807 - $153,038	32,151 Added 1345.23%	34,541 $93,000
Q3 2021 Oct 28, 2021	BUY	$4.06 - $5.8 $405 - $580	100 Added 4.37%	2,390 $13,000
Q2 2021 Aug 12, 2021	SELL	$5.02 - $7.05 $188,074 - $264,128	-37,465 Reduced 94.24%	2,290 $13,000
Q1 2021 Apr 26, 2021	BUY	$4.81 - $10.34 $189,778 - $407,964	39,455 Added 13151.67%	39,755 $279,000
Q4 2020 Feb 02, 2021	BUY	$4.13 - $6.41 $1,239 - $1,923	300 New	300 $1,000
Q3 2019 Oct 15, 2019	SELL	$3.93 - $15.35 $262,288 - $1.02 Million	-66,740 Closed	0 $0
Q2 2019 Jul 26, 2019	BUY	$12.81 - $25.67 $418,246 - $838,125	32,650 Added 95.78%	66,740 $992,000
Q1 2019 Apr 18, 2019	SELL	$17.66 - $30.28 $851,582 - $1.46 Million	-48,221 Reduced 58.58%	34,090 $0
Q4 2018 Jan 16, 2019	BUY	$11.63 - $32.67 $558,053 - $1.57 Million	47,984 Added 139.79%	82,311 $1.48 Million
Q3 2018 Oct 23, 2018	BUY	$29.37 - $49.48 $682,176 - $1.15 Million	23,227 Added 209.25%	34,327 $1.01 Million
Q2 2018 Jul 30, 2018	SELL	$42.06 - $62.4 $252,444 - $374,524	-6,002 Reduced 35.1%	11,100 $504,000
Q1 2018 Apr 26, 2018	SELL	$50.12 - $67.72 $1.29 Million - $1.74 Million	-25,650 Reduced 60.0%	17,102 $902,000
Q4 2017 Jan 10, 2018	BUY	$57.69 - $84.58 $885,483 - $1.3 Million	15,349 Added 56.01%	42,752 $2.91 Million
Q3 2017 Oct 25, 2017	BUY	$67.17 - $84.81 $1.84 Million - $2.32 Million	27,403	27,403 $2.26 Million

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account